Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis

BACKGROUND: Immune checkpoint inhibitors, which are a milestone in anti-cancer therapy, have been applied in the treatment of multiple malignancies. Real-world data have suggested that smoking status may be associated with the efficacy of anti-PD-1/PD-L1 therapy. Hereby, to evaluate “smoking benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Mo, Jiahang, Hu, Xiao, Gu, Lihu, Chen, Bangsheng, Khadaroo, Parikshit Asutosh, Shen, Zefeng, Dong, Lei, Lv, Yuqi, Chitumba, Marylin Nyaradzo, Liu, Jiequan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971889/
https://www.ncbi.nlm.nih.gov/pubmed/31959178
http://dx.doi.org/10.1186/s12957-020-1792-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6971889/
https://www.ncbi.nlm.nih.gov/pubmed/31959178
http://dx.doi.org/10.1186/s12957-020-1792-4

Ejemplares similares